The FDA’s clearance could double Kisqali’s breast cancer market. Elsewhere, Novo is exploring new ways to deliver genetic ...

Today, a brief rundown of news from Novartis and GSK, as well as updates from Omega Funds, Serán Bioscience and Boehringer Ingelheim that you may have missed.

GSK plc (NYSE:GSK) is a British pharmaceutical ... Right now, its two hottest drugs are Scemblix and Kisqali, which are used to help patients with leukemia and breast cancer and as an adjuvant ...

GSK has turned to Brooke Shields to get the message out about shingles vaccination. The drugmaker has worked with the model and actor to talk to female celebrities and patients aged 50 years and ...

This summer, GSK cut its yearly vaccine sales projection on the back of a narrowed recommendation for adult respiratory syncytial virus (RSV) vaccines from the Centers for Disease Control and ...

After an initial defeat against the biggest barrier to mRNA flu vaccines—namely, B strains of influenza—GSK has returned with a reformulated candidate that has delivered the goods in the all ...

GSK Says mRNA Flu Shot Shows Promise in Boost for Pipeline GSK could beat Pfizer to market, says chief commercial officer Several drugmakers are betting on mRNA seasonal flu vaccines ...

GSK Plc’s experimental vaccine for herpes failed in an early-stage trial, halting an effort to bring the first shot for the condition to market. While there were no safety concerns, the trial ...

Among adults aged 60 years and older, the societal cost per QALY saved was $196,842 for GSK’s Arexvy and $178,557 for Pfizer’s Abrysvo. 1 For adults aged 65 years and older, the cost was $ ...

Roche has now beat Merck and Bristol Myers to market with its under-the-skin immunotherapy. Elsewhere, Sanofi bought into radiopharmaceuticals and Mene Pangalos joined Biogen's board.